• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hyperprogression with immunotherapy: Is it real?

作者信息

Popat Sanjay

机构信息

Department of Medicine, Royal Marsden Hospital, London, United Kingdom.

Genomic Medicine, National Heart and Lung Institute, Imperial College London, London, United Kingdom.

出版信息

Cancer. 2019 Apr 15;125(8):1218-1220. doi: 10.1002/cncr.31997. Epub 2019 Feb 15.

DOI:10.1002/cncr.31997
PMID:30768797
Abstract
摘要

相似文献

1
Hyperprogression with immunotherapy: Is it real?免疫疗法导致的超进展：是真的吗？
Cancer. 2019 Apr 15;125(8):1218-1220. doi: 10.1002/cncr.31997. Epub 2019 Feb 15.
2
Hyperprogression after immunotherapy in patients with malignant tumors of digestive system.免疫治疗后消化系统恶性肿瘤患者的超进展。
BMC Cancer. 2019 Jul 17;19(1):705. doi: 10.1186/s12885-019-5921-9.
3
Pseudoprogression and hyperprogression after checkpoint blockade.免疫检查点抑制剂治疗后的假性进展和超进展。
Int Immunopharmacol. 2018 May;58:125-135. doi: 10.1016/j.intimp.2018.03.018. Epub 2018 Mar 23.
4
Immunotherapy and Hyperprogression: Unwanted Outcomes, Unclear Mechanism.免疫疗法与超进展：不良结局，机制不明。
Clin Cancer Res. 2019 Feb 1;25(3):904-906. doi: 10.1158/1078-0432.CCR-18-3144. Epub 2018 Nov 5.
5
Characterization of Hyperprogression After Immunotherapy in a Lung Adenocarcinoma Patient With Strong Expression of Programmed Death Ligand 1.程序性死亡配体1强表达的肺腺癌患者免疫治疗后超进展的特征分析
J Thorac Oncol. 2020 Jan;15(1):e4-e8. doi: 10.1016/j.jtho.2019.08.007.
6
Hyperprogression under Immunotherapy.免疫治疗下的超进展。
Int J Mol Sci. 2019 May 30;20(11):2674. doi: 10.3390/ijms20112674.
7
NK Cells Respond to Checkpoint Blockade.自然杀伤细胞对免疫检查点阻断产生反应。
Cancer Discov. 2018 Dec;8(12):1498. doi: 10.1158/2159-8290.CD-NB2018-131. Epub 2018 Oct 23.
8
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out.明智选择非小细胞肺癌（NSCLC）一线免疫治疗：该加什么，该弃什么。
Cancer Treat Rev. 2019 May;75:39-51. doi: 10.1016/j.ctrv.2019.03.004. Epub 2019 Mar 28.
9
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.免疫治疗后的超进展者：与加速生长率相关的基因组改变分析。
Clin Cancer Res. 2017 Aug 1;23(15):4242-4250. doi: 10.1158/1078-0432.CCR-16-3133. Epub 2017 Mar 28.
10
Saved From Sepsis: Can Immunotherapy Improve Acute and Postacute Outcomes?
Crit Care Med. 2019 May;47(5):733-735. doi: 10.1097/CCM.0000000000003702.

引用本文的文献

1
Case report: Fast disease progression during adjuvant therapy with anti-PD-1 in stage III melanoma patients.病例报告：III期黑色素瘤患者在接受抗PD-1辅助治疗期间疾病进展迅速。
Front Oncol. 2024 Aug 1;14:1437325. doi: 10.3389/fonc.2024.1437325. eCollection 2024.
2
Inhibition of hyperprogressive cancer disease induced by immune-checkpoint blockade upon co-treatment with meta-tyrosine and p38 pathway inhibitor.Meta 酪氨酸与 p38 通路抑制剂联用抑制免疫检查点阻断后引起的超进展性癌症疾病。
BMC Cancer. 2022 Aug 3;22(1):845. doi: 10.1186/s12885-022-09941-2.
3
Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort.
使用扩展队列更新接受免疫检查点抑制剂治疗的头颈部鳞状细胞癌患者的预后生存模型。
BMC Cancer. 2022 Jul 14;22(1):767. doi: 10.1186/s12885-022-09809-5.
4
Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors.使用两种免疫检查点抑制剂治疗的超进展性非小细胞肺癌
JTO Clin Res Rep. 2020 Feb 22;1(2):100017. doi: 10.1016/j.jtocrr.2020.100017. eCollection 2020 Jun.
5
Hyperprogression under immunotherapy: a new form of immunotherapy response?-a narrative literature review.免疫治疗下的超进展：一种新的免疫治疗反应形式？——一篇叙述性文献综述
Transl Lung Cancer Res. 2021 Jul;10(7):3276-3291. doi: 10.21037/tlcr-21-575.
6
Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma.免疫疗法在恶性胸膜间皮瘤治疗中的新途径。
BMC Pulm Med. 2021 May 5;21(1):148. doi: 10.1186/s12890-021-01513-7.
7
Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma.肝细胞癌中一种免疫相关预后预测指标的鉴定
Front Mol Biosci. 2020 Sep 24;7:567950. doi: 10.3389/fmolb.2020.567950. eCollection 2020.
8
Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses.免疫检查点抑制剂治疗后的超进展：特征与假说
Front Oncol. 2020 Apr 29;10:515. doi: 10.3389/fonc.2020.00515. eCollection 2020.
9
Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives.间皮瘤的免疫疗法：对当前临床试验及未来前景的批判性综述
Transl Lung Cancer Res. 2020 Feb;9(Suppl 1):S100-S119. doi: 10.21037/tlcr.2019.11.23.
10
Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?超进展与免疫检查点抑制剂：炒作还是进展？
Oncologist. 2020 Feb;25(2):94-98. doi: 10.1634/theoncologist.2019-0636. Epub 2019 Nov 20.